patent on semaglutide expires next year: Novo Nordisk faces tough competition in the Chinese obesity market Post-patent Semaglutide Launch Race Begins

The researchers noted that many of the studies were too small, short, and poorly designed to draw any real conclusions about the supplements being investigated

Your timeline matters: if you've been on semaglutide for several months and achieved significant weight loss, stopping medication may not reverse progress if healthy behaviors remain in place

Your provider needs to assess whether your post-cholecystectomy gut physiology can tolerate these additional changes without triggering diarrhea, fat malabsorption, or other gastrointestinal complications

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial